PH26226A - Phenethanolamine and growth hormone combinations - Google Patents

Phenethanolamine and growth hormone combinations Download PDF

Info

Publication number: PH26226A
Authority: PH; Philippines
Prior art keywords: growth hormone; ractopamine; pigs; cimaterol; clenbuterol
Prior art date: 1988-03-07

Application number

PH38287A

Other languages

English (en)

Inventor

David Bennett Anderson

Darrell Jay Jones

Alvin Leo Melleire

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-03-07

Filing date

1989-03-06

Publication date

1992-04-01

1989-03-06 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1992-04-01 Publication of PH26226A publication Critical patent/PH26226A/en

Links

108010051696 Growth Hormone Proteins 0.000 title claims abstract description 44
102000018997 Growth Hormone Human genes 0.000 title claims abstract description 44
239000000122 growth hormone Substances 0.000 title claims abstract description 43
ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 title description 4
229950006768 phenylethanolamine Drugs 0.000 title description 4
YJQZYXCXBBCEAQ-UHFFFAOYSA-N ractopamine Chemical compound C=1C=C(O)C=CC=1C(O)CNC(C)CCC1=CC=C(O)C=C1 YJQZYXCXBBCEAQ-UHFFFAOYSA-N 0.000 claims abstract description 49
229940074095 ractopamine Drugs 0.000 claims abstract description 42
239000000126 substance Substances 0.000 claims abstract description 27
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 20
BUXRLJCGHZZYNE-UHFFFAOYSA-N 2-amino-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzonitrile Chemical compound CC(C)NCC(O)C1=CC=C(N)C(C#N)=C1 BUXRLJCGHZZYNE-UHFFFAOYSA-N 0.000 claims abstract description 15
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims abstract description 15
229950010971 cimaterol Drugs 0.000 claims abstract description 15
229960001117 clenbuterol Drugs 0.000 claims abstract description 15
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims abstract description 15
229960002052 salbutamol Drugs 0.000 claims abstract description 15
BSDXBEZQZYKYHH-UHFFFAOYSA-N 1-(6-aminopyridin-3-yl)-2-(4-phenylbutan-2-ylamino)ethanol Chemical compound C=1C=C(N)N=CC=1C(O)CNC(C)CCC1=CC=CC=C1 BSDXBEZQZYKYHH-UHFFFAOYSA-N 0.000 claims abstract description 12
102000004877 Insulin Human genes 0.000 claims abstract description 10
108090001061 Insulin Proteins 0.000 claims abstract description 10
229940125396 insulin Drugs 0.000 claims abstract description 10
210000004369 blood Anatomy 0.000 claims abstract description 7
239000008280 blood Substances 0.000 claims abstract description 7
235000005911 diet Nutrition 0.000 claims description 29
230000037213 diet Effects 0.000 claims description 29
235000019750 Crude protein Nutrition 0.000 claims description 25
241000282887 Suidae Species 0.000 claims description 19
238000000034 method Methods 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 10
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims description 4
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 4
101710142969 Somatoliberin Proteins 0.000 claims description 4
230000001603 reducing effect Effects 0.000 claims description 3
241000282898 Sus scrofa Species 0.000 abstract description 11
241001465754 Metazoa Species 0.000 description 31
238000011282 treatment Methods 0.000 description 31
102000004169 proteins and genes Human genes 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
235000018102 proteins Nutrition 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
239000008057 potassium phosphate buffer Substances 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
239000008103 glucose Substances 0.000 description 6
238000005303 weighing Methods 0.000 description 6
239000004615 ingredient Substances 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000007929 subcutaneous injection Substances 0.000 description 5
238000010254 subcutaneous injection Methods 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
229960005419 nitrogen Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
229940046545 animal allergen extract Drugs 0.000 description 3
230000035611 feeding Effects 0.000 description 3
239000007952 growth promoter Substances 0.000 description 3
239000007943 implant Substances 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000011707 mineral Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
-1 1,1-di- methylethyl Chemical group 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
229960004217 benzyl alcohol Drugs 0.000 description 2
230000037396 body weight Effects 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
230000003345 hyperglycaemic effect Effects 0.000 description 2
230000000910 hyperinsulinemic effect Effects 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
235000019737 Animal fat Nutrition 0.000 description 1
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
102000015781 Dietary Proteins Human genes 0.000 description 1
108010010256 Dietary Proteins Proteins 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
239000000039 congener Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000021245 dietary protein Nutrition 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000003371 gabaergic effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000007775 late Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
239000000047 product Substances 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
229940070376 protein Drugs 0.000 description 1
238000003044 randomized block design Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Polymers & Plastics (AREA)
Endocrinology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Food Science & Technology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Husbandry (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Birds (AREA)
Diabetes (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Fodder In General (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Feed For Specific Animals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PH38287A 1988-03-07 1989-03-06 Phenethanolamine and growth hormone combinations PH26226A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16467588A	1988-03-07	1988-03-07

Publications (1)

Publication Number	Publication Date
PH26226A true PH26226A (en)	1992-04-01

Family

ID=22595564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH38287A PH26226A (en)	1988-03-07	1989-03-06	Phenethanolamine and growth hormone combinations

Country Status (14)

Country	Link
EP (1)	EP0333349B1 (de)
JP (1)	JP2780994B2 (de)
KR (1)	KR0129755B1 (de)
AT (1)	ATE104143T1 (de)
CA (1)	CA1336886C (de)
DE (1)	DE68914498T2 (de)
DK (1)	DK173510B1 (de)
ES (1)	ES2061974T3 (de)
HU (1)	HU204696B (de)
IE (1)	IE63407B1 (de)
IL (1)	IL89479A (de)
NZ (1)	NZ228197A (de)
PH (1)	PH26226A (de)
ZA (1)	ZA891588B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5453418A (en) *	1988-03-07	1995-09-26	Eli Lilly And Company	Ractopamine and growth hormone combinations
DE69231467T2 (de)	1991-05-10	2001-01-25	Genentech, Inc.	Auswählen von agonisten und antagonisten von liganden
US6429186B1 (en)	1991-05-10	2002-08-06	Genentech, Inc.	Ligand antagonists for treatment of breast cancer
US5216029A (en) *	1991-11-26	1993-06-01	Eli Lilly And Company	Fish production
US5595752A (en) *	1994-07-01	1997-01-21	Monsanto Company	Increasing dressing percentage and carcass weight in finishing beef cattle
CN103100237B (zh) *	2012-12-31	2015-12-02	南宁市蓝光生物技术有限公司	微型高效莱克多巴胺免疫亲和纯化富集柱制备及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4690951A (en) *	1983-01-31	1987-09-01	Eli Lilly And Company	Growth promotion
US4792546A (en) *	1986-12-05	1988-12-20	American Cyanamid Company	Method for increasing weight gains and reducing deposition of fat in animals
IE60964B1 (en) *	1986-12-11	1994-09-07	Roussel Uclaf	Zootechnical compositions containing a beta-adrenergic

1989
- 1989-03-01 ZA ZA891588A patent/ZA891588B/xx unknown
- 1989-03-01 CA CA000592486A patent/CA1336886C/en not_active Expired - Fee Related
- 1989-03-02 NZ NZ228197A patent/NZ228197A/en unknown
- 1989-03-02 ES ES89302096T patent/ES2061974T3/es not_active Expired - Lifetime
- 1989-03-02 AT AT89302096T patent/ATE104143T1/de not_active IP Right Cessation
- 1989-03-02 DE DE68914498T patent/DE68914498T2/de not_active Expired - Fee Related
- 1989-03-02 EP EP89302096A patent/EP0333349B1/de not_active Expired - Lifetime
- 1989-03-03 IL IL8947989A patent/IL89479A/en not_active IP Right Cessation
- 1989-03-06 HU HU891099A patent/HU204696B/hu not_active IP Right Cessation
- 1989-03-06 PH PH38287A patent/PH26226A/en unknown
- 1989-03-06 KR KR1019890002727A patent/KR0129755B1/ko not_active Expired - Fee Related
- 1989-03-06 DK DK198901061A patent/DK173510B1/da not_active IP Right Cessation
- 1989-03-06 IE IE71689A patent/IE63407B1/en not_active IP Right Cessation
- 1989-03-07 JP JP1054833A patent/JP2780994B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IE63407B1 (en)	1995-04-19
HU204696B (en)	1992-02-28
DE68914498T2 (de)	1994-08-18
IL89479A (en)	1994-08-26
KR890014099A (ko)	1989-10-21
EP0333349A2 (de)	1989-09-20
NZ228197A (en)	1991-07-26
KR0129755B1 (ko)	1998-04-09
ZA891588B (en)	1990-11-28
ATE104143T1 (de)	1994-04-15
JP2780994B2 (ja)	1998-07-30
AU3102789A (en)	1989-09-07
HUT49281A (en)	1989-09-28
ES2061974T3 (es)	1994-12-16
DK173510B1 (da)	2001-01-15
DE68914498D1 (de)	1994-05-19
IL89479A0 (en)	1989-09-10
EP0333349A3 (en)	1990-12-05
DK106189A (da)	1989-10-20
CA1336886C (en)	1995-09-05
DK106189D0 (da)	1989-03-06
AU617155B2 (en)	1991-11-21
JPH01268643A (ja)	1989-10-26
EP0333349B1 (de)	1994-04-13
IE890716L (en)	1989-09-07

Publication	Publication Date	Title
EP0192360B1 (de)	1991-12-18	Verfahren zur Erhöhung der Futteraufnahme eines Tieres
US4670249A (en)	1987-06-02	Growth-promoting compositions
US5453418A (en)	1995-09-26	Ractopamine and growth hormone combinations
US5004728A (en)	1991-04-02	Methods of increasing milk yields in ruminants
CA1336886C (en)	1995-09-05	Phenethanolamine and growth hormone combinations
US5122512A (en)	1992-06-16	Swine growth promoting composition
Slaba et al.	1994	Plasma profiles of somatotropin and IGF-I in dairy cows following application of two preparations of recombinant bovine somatotropin in a sustained release vehicle
JPH10502368A (ja)	1998-03-03	インシュリン及びｉｇｆ−ｉの使用
US4851402A (en)	1989-07-25	Estriol growth promotant
EP0292517B1 (de)	1992-09-09	Verbesserungen im gebrauch oder in bezug auf den gebrauch von egf
Gülay et al.	2005	Use of bovine somatotropin in the management of transition dairy cows
Johnson et al.	1990	The effect of human growth hormone-releasing factor or porcine somatotropin on serum hormones and metabolites, growth performance and carcass traits in swine
Eisenbeisz	1988	Lactational evaluation of recombinant bovine somatotropin with corn and barley diets
Geay et al.	1992	Effects of feeding sorbitol associated with different sources and amounts of nitrogen on growth, digestion and metabolism in young bulls